COMPARISON OF ORAL ANTICOAGULANTS and ANTIPLATELETS

Drug Name/s and common dose	Indications	Reversal agents
Pradaxa, Pradax Anticoagulant Dabigatran (direct thrombin inhibitor): *150mg BID*	AFib, prevention VTE (off label)	experimental evidence for using activated prothrombin complex concentrate (*FEIBA*) or recombinant factor VIIa
Xarelto Anticoagulant Rivaroxaban (direct factor Xa inhibitor): *10mg qd*	VTE prevention, afib and DVT (off label)	activated prothrombin complex concentrate, prothrombin complex concentrate (*Beriplex P/N*), or recombinant factor VIIa
Coumadin Anticoagulant Warfarin (inhibits formation of vit K dependent clotting factors): Dose varies	Prevention/treatment venous thrombosis/PE, Prevention/treatment of thromboembolism due to Afib or prosthetic heart valve	Vit K Prothrombin Complex Concentrate Factor VII
Aspirin Antiplatelet (inhibits cyclo-oxygenase) Dose varies	Secondary prevention after ischemic stroke, TIA, MI, or unstable angina	Platelet transfusion
Pletal Antiplatelet Cilostazol (inhibits platelet phosphodiesterase III) 100mg bid	Intermittent claudication	No specific antidote
Plavix Antiplatelet Clopidogrel (blocks platelet ADP P2Y12 receptor) 75mg qd	ACS, recent stroke, recent MI, peripheral artery disease	Platelet transfusion DDAVP
Persantine Antiplatelet Dipyridamole (inhibits platelet adenosine uptake) 75-100 mg qid	Prevention of thromboembolism post-heart valve replacement, (with warfarin)	No specific antidote
Aggrenox Antiplatelet Dipyridamole extended release 200mg/aspirin 25mg (inhibits cyclo-oxygenase and inhibits platelet adenosine uptake) one capsule bid	Secondary prevention of stroke post-stroke/TIA	Platelet transfusion for ASA
Effient Antiplatelet Prasugrel (blocks platelet ADP P2Y12 receptor) 10mg qd	ACS managed with PCI (including stenting), with ASA	Platelet transfusion
Brilinta Antiplatelet Ticagrelor (blocks platelet ADP P2Y12 receptor) 90mg bid	ACS	Aminocaproic acid or tranexamic acid and/or factor VIIa
Ticlopidine Antiplatelet (blocks platelet ADP P2Y12 receptor) 250mg bid	Secondary prevention of stroke post-stroke/TIA Prevention of stent thrombosis	Platelet transfusion